Adaptive Biotechnologies Corp (ADPT) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Adaptive Biotechnologies is a commercial-stage company advancing immune medicine through its Minimal Residual Disease (MRD) and Immune Medicine business areas. The company's primary product is the clonoSEQ test, used for detecting and monitoring MRD in lymphoid cancers. The company operates with a significant accumulated deficit and relies on cash reserves, revenue, and a revenue interest purchase agreement to fund operations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $70.9 million | $52.4 million |
| Net Loss (GAAP) | $(20.0) million | $(29.9) million |
| Net Loss Per Share | $(0.13) | $(0.20) |
| Adjusted EBITDA | $(2.5) million | $(12.7) million |
| Cash & Marketable Securities | $237.2 million | $240.2 million (Dec 31, 2025) |
| Revenue Interest Liability | $130.6 million | $131.2 million (Dec 31, 2025) |
| Operating Cash Flow | $(9.5) million | $(28.5) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 35% year-over-year, driven primarily by a 53% increase in MRD revenue to $67.1 million. This was fueled by a 41% increase in clonoSEQ test volume (32,595 tests) and $4.5 million in regulatory milestone revenue.
- Immune Medicine Decline: Immune Medicine revenue decreased 57% to $3.8 million, primarily due to the termination of the Genentech collaboration agreement in August 2025, which eliminated $3.6 million in collaboration revenue.
- Profitability Improvement: The net loss narrowed by approximately $9.8 million compared to Q1 2025. Adjusted EBITDA improved significantly from a deficit of $12.7 million to $2.5 million.
- Expense Management: Research and Development expenses decreased slightly by 2% to $23.6 million. However, Sales and Marketing expenses rose 14% to $26.3 million, and General and Administrative expenses increased 21% to $21.0 million.
Outlook, Risks, and Commentary
- Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($237.2 million) are sufficient to fund operations for at least the next 12 months.
- Revenue Interest Liability: The company has a debt-like obligation to OrbiMed based on a percentage of GAAP revenue. The effective interest rate was 8.9% as of March 31, 2026. Future interest expense is sensitive to revenue forecasts.
- Future Milestones: The company could receive up to $386.0 million in future milestone payments if customers achieve regulatory approvals for therapeutics using MRD data. Additionally, a target discovery agreement offers potential milestones up to $877.5 million.
- Risks: Key risks include the novelty of immune medicine, reliance on third-party collaborators for clinical testing, reimbursement uncertainties for clonoSEQ, and the potential for future capital raises which could dilute shareholders.
- Insider Trading Plans: On March 13, 2026, the Chief Scientific Officer adopted a Rule 10b5-1 plan to sell up to 984,800 shares. The CFO terminated a similar plan on March 16, 2026.
Investor Verification Checklist
- Verify the sustainability of the 41% increase in clonoSEQ test volume and the impact of the new Medicare episode pricing ($8,029) on future revenue recognition.
- Assess the impact of the terminated Genentech agreement on the long-term trajectory of the Immune Medicine segment.
- Monitor the "Revenue Interest Liability" balance and the effective interest rate, as higher revenue increases the cash outflow required to service this obligation.
- Review the timing of potential regulatory milestone payments ($386M potential) to understand future revenue volatility.
- Confirm the company's burn rate relative to its $237.2 million cash position to validate the 12-month liquidity runway.